Julie Kim | CEO-Elect

Julie Kim is president, chief executive officer (CEO) and representative director of Takeda. She was elected by shareholders and appointed by the Board of Directors in June 2026. She joined the company in 2019 through the acquisition of Shire and held several executive-level roles, including president of the Plasma-Derived Therapies Business Unit and president of the U.S. Business Unit before becoming CEO-elect in 2025.

Julie is leading Takeda into its next era to make an expanded impact on the lives of patients and bring increased value to its shareholders. The company is launching multiple new products while advancing the most robust pipeline in the company’s history and transforming itself through advanced technology to operate with speed and growth.

Prior to Takeda, Julie held roles of increasing responsibility at Baxter, Baxalta and Shire spanning global, regional and country-level roles across a variety of therapeutic areas and markets. Her global outlook, a result of having worked and lived in many countries and regions, including the U.K., Switzerland, China's Hong Kong and the U.S., has helped her foster diverse teams to enable inclusive decision-making that keeps the patient at the center.

A committed community and industry leader, Julie was appointed by the Mayor of Boston to the Board of Trustees of the Boston Public Library, one of the most iconic and respected institutions in the city. She also serves on the board of the Pharmaceutical Research and Manufacturers of America (PhRMA), leading the International Committee, and is a member of the Council of Korean Americans.

Julie holds an MBA from the J. L. Kellogg Graduate School of Management at Northwestern University and a bachelor’s degree in economics from Dartmouth College. Julie splits her time between Boston and Tokyo, where Takeda is headquartered.